102 related articles for article (PubMed ID: 10842197)
1. Flt3 ligand lessens the growth of tumors obtained after colon cancer cell injection in rats but does not restore tumor-suppressed dendritic cell function.
Favre-Felix N; Martin M; Maraskovsky E; Fromentin A; Moutet M; Solary E; Martin F; Bonnotte B
Int J Cancer; 2000 Jun; 86(6):827-34. PubMed ID: 10842197
[TBL] [Abstract][Full Text] [Related]
2. FLT3 ligand administration after hematopoietic cell transplantation increases circulating dendritic cell precursors that can be activated by CpG oligodeoxynucleotides to enhance T-cell and natural killer cell function.
Chen W; Chan AS; Dawson AJ; Liang X; Blazar BR; Miller JS
Biol Blood Marrow Transplant; 2005 Jan; 11(1):23-34. PubMed ID: 15625541
[TBL] [Abstract][Full Text] [Related]
3. Tumor-infiltrating dendritic cells are defective in their antigen-presenting function and inducible B7 expression in rats.
Chaux P; Favre N; Martin M; Martin F
Int J Cancer; 1997 Aug; 72(4):619-24. PubMed ID: 9259401
[TBL] [Abstract][Full Text] [Related]
4. Expansion of functional NK cells in multiple tissue compartments of mice treated with Flt3-ligand: implications for anti-cancer and anti-viral therapy.
Shaw SG; Maung AA; Steptoe RJ; Thomson AW; Vujanovic NL
J Immunol; 1998 Sep; 161(6):2817-24. PubMed ID: 9743341
[TBL] [Abstract][Full Text] [Related]
5. Combinational FLt3 ligand and granulocyte macrophage colony-stimulating factor treatment promotes enhanced tumor infiltration by dendritic cells and antitumor CD8(+) T-cell cross-priming but is ineffective as a therapy.
Berhanu A; Huang J; Alber SM; Watkins SC; Storkus WJ
Cancer Res; 2006 May; 66(9):4895-903. PubMed ID: 16651446
[TBL] [Abstract][Full Text] [Related]
6. Sensitivity of dendritic cells to NK-mediated lysis depends on the inflammatory environment and is modulated by CD54/CD226-driven interactions.
Smith LE; Olszewski MA; Georgoudaki AM; Wagner AK; Hägglöf T; Karlsson MC; Dominguez-Villar M; Garcia-Cozar F; Mueller S; Ravens I; Bernhardt G; Chambers BJ
J Leukoc Biol; 2016 Oct; 100(4):781-789. PubMed ID: 27034402
[TBL] [Abstract][Full Text] [Related]
7. NK cells mediate Flt3 ligand-induced protection of dendritic cell precursors in vivo from the inhibition by prostate carcinoma in the murine bone marrow metastasis model.
Tourkova IL; Yamabe K; Chatta G; Shurin GV; Shurin MR
J Immunother; 2003; 26(6):468-72. PubMed ID: 14595214
[TBL] [Abstract][Full Text] [Related]
8. Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified.
Maraskovsky E; Brasel K; Teepe M; Roux ER; Lyman SD; Shortman K; McKenna HJ
J Exp Med; 1996 Nov; 184(5):1953-62. PubMed ID: 8920882
[TBL] [Abstract][Full Text] [Related]
9. Rapid generation of potent and tumor-specific cytotoxic T lymphocytes by interleukin 18 using dendritic cells and natural killer cells.
Tanaka F; Hashimoto W; Okamura H; Robbins PD; Lotze MT; Tahara H
Cancer Res; 2000 Sep; 60(17):4838-44. PubMed ID: 10987295
[TBL] [Abstract][Full Text] [Related]
10. Murine Flt3 ligand expands distinct dendritic cells with both tolerogenic and immunogenic properties.
Miller G; Pillarisetty VG; Shah AB; Lahrs S; DeMatteo RP
J Immunol; 2003 Apr; 170(7):3554-64. PubMed ID: 12646617
[TBL] [Abstract][Full Text] [Related]
11. Flt3-L gene therapy enhances immunocytokine-mediated antitumor effects and induces long-term memory.
Neal ZC; Sondel PM; Bates MK; Gillies SD; Herweijer H
Cancer Immunol Immunother; 2007 Nov; 56(11):1765-74. PubMed ID: 17426968
[TBL] [Abstract][Full Text] [Related]
12. Effect of Flt3 ligand gene transfer in experimental pancreatic cancer.
Ryschich E; Huszty G; Wentzensen N; Schmidt E; Knaebel HP; Encke J; Märten A; Büchler MW; Schmidt J
Int J Colorectal Dis; 2007 Feb; 22(2):215-23. PubMed ID: 16528542
[TBL] [Abstract][Full Text] [Related]
13. Effect of vascular endothelial growth factor and FLT3 ligand on dendritic cell generation in vivo.
Ohm JE; Shurin MR; Esche C; Lotze MT; Carbone DP; Gabrilovich DI
J Immunol; 1999 Sep; 163(6):3260-8. PubMed ID: 10477595
[TBL] [Abstract][Full Text] [Related]
14. Enhancing effects of (2S,3S,4R)-1-O-(alpha-D-galactopyranosyl)-2-(N-hexacosanoylamino) -1,3,4-octadecanetriol (KRN7000) on antigen-presenting function of antigen-presenting cells and antimetastatic activity of KRN7000-pretreated antigen-presenting cells.
Yamaguchi Y; Motoki K; Ueno H; Maeda K; Kobayashi E; Inoue H; Fukushima H; Koezuka Y
Oncol Res; 1996; 8(10-11):399-407. PubMed ID: 9114432
[TBL] [Abstract][Full Text] [Related]
15. Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated.
Demaria S; Ng B; Devitt ML; Babb JS; Kawashima N; Liebes L; Formenti SC
Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):862-70. PubMed ID: 14967443
[TBL] [Abstract][Full Text] [Related]
16. Dendritic cell-induced activation of adaptive and innate antitumor immunity.
van den Broeke LT; Daschbach E; Thomas EK; Andringa G; Berzofsky JA
J Immunol; 2003 Dec; 171(11):5842-52. PubMed ID: 14634094
[TBL] [Abstract][Full Text] [Related]
17. Chemotherapy agents stimulate dendritic cells against human colon cancer cells through upregulation of the transporter associated with antigen processing.
Liang YH; Tsai JH; Cheng YM; Chan KY; Hsu WL; Lee CC; Chen KH; Yeh KH
Sci Rep; 2021 Apr; 11(1):9080. PubMed ID: 33907276
[TBL] [Abstract][Full Text] [Related]
18. Generating a T cell tumor-specific immune response in vivo: can flt3-ligand-generated dendritic cells tip the balance?
McKenna HJ
Cancer Immunol Immunother; 1999 Sep; 48(6):281-6. PubMed ID: 10473802
[TBL] [Abstract][Full Text] [Related]
19. Rat bone marrow-derived dendritic cells generated with GM-CSF/IL-4 or FLT3L exhibit distinct phenotypical and functional characteristics.
N'diaye M; Warnecke A; Flytzani S; Abdelmagid N; Ruhrmann S; Olsson T; Jagodic M; Harris RA; Guerreiro-Cacais AO
J Leukoc Biol; 2016 Mar; 99(3):437-46. PubMed ID: 26516183
[TBL] [Abstract][Full Text] [Related]
20. Induction of potent antitumor immunity by in situ targeting of intratumoral DCs.
Furumoto K; Soares L; Engleman EG; Merad M
J Clin Invest; 2004 Mar; 113(5):774-83. PubMed ID: 14991076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
